Recently, it was shown that dinaciclib (cyclin-dependent kinase inhibitor) downregulates KP-related genes such as IDO1, TDO2, KYAT1-4, and KMO in patient-derived GBM cell lines [122]. Here, TDO2 is linked to glioblastoma.